Page 400 - ONLINE PROCEEDING BOOK WSAVA 2017
P. 400

An Urban Experience
Figure 7. Recent information on the role of interleukin-31 (IL-31) in dogs with atopic dermatitis, led to development of a caninized anti-cIL-31 monoclonal antibody (Cytopointâ). Whereas Apoquelâ works by binding and blocking the JAK after the cytokines bind the receptor, Cytopointâ neutralizes only the IL-31 cytokine before binding to the receptor.
Allergy Testing and Immunotherapy
Allergen-speci c immunotherapy (ASIT) is a treatment for AD in dogs and cats wherein
extracts of allergens to which the patient is sensitive are injected or administered orally, in gradually increasing amounts, to lessen or reverse the hypersensitivity state (Figure 8). Allergy testing, either intradermal or allergen- speci c IgE serology, is used as a prelude to ASIT. Allergy tests do not answer the question “Is this pruritic patient atopic?” because some normal and nonatopic patients also have positive test results. In addition, a small percentage of dogs diagnosed with atopic dermatitis have no measurable increase in allergen-speci c IgE. This is referred to as “intrinsic” AD.
Figure 8. Allergen-speci c immunotherapy (ASIT) is a treatment for AD in dogs and cats wherein extracts of allergens to which the patient
is sensitive are injected or administered orally, in gradually increasing amounts, to lessen or reverse the hypersensitivity state. Intradermal or allergen-speci c IgE allergy testing precedes ASIT.
Allergy tests are useful in those patients where a
diagnosis of AD has been made by ruling out other causes of pruritus and, therefore, are candidates
for ASIT. This is the only treatment that may reverse part of the underlying pathogenesis of the disease. Immunotherapy is thought to normalize the immune response by increased production of T regulatory cells and anti-in ammatory cytokines that reduce the Th2 in ammatory cascade. The chief disadvantages are that it takes several months or more to begin working and that only 60% to 70% of dogs experience a “good-to-excellent” response (de ned as at least 50% improvement in clinical signs) after 1 year of treatment.
Sources
Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the ef cacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24:587-e142. Cosgrove SB, Wren JA, Cleaver DM, et al. Ef cacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24:479-e114.
Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates in ammation and pruritus in Th2-dependent dermal in ammation. J Invest Dermatol. 2010;130:1023-1033.
Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol. 2011;25:334-339.
Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. Curr Probl Dermatol. 2011;41:1-34.
Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. (2014) Ef cacy
of oclacitinib (Apoquelâ) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25:512-e86.
Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol. 2009;18:35-43.
Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. Vet Dermatol. 2010;21:456- 462.
Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, randomized clinical trial comparing the ef cacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26:23-e8. Marsella R, Olivry T, Carlotti DN for the International Task Force on Canine Atopic Dermatitis. Current evidence of skin barrier dysfunction in human and canine atopic dermatitis. Vet Dermatol. 2011;22:239-248.
Metz M, Grundmann S, Ständer S. Pruritus: an overview of current concepts. Vet Dermatol. 2011;22:121-131.
Michels GM, Ramsey DS, Walsh KF, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol. 2016;27:478-e129.
Michels GM, Walsh KF, Kryda KA, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol. 2016;27:505-e136.
Mommert S, Gschwandtner M, Gutzmer R, Werfel T. The role of the histamine H4 receptor in atopic dermatitis. Curr Allergy Asthma Rep. 2011;11:21-28.
Olivry T, Mueller RS for the International Task Force on Canine Atopic Dermatitis. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol. 2003;14:121-146.
Olivry T, DeBoer D, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21:233-248.
Olivry T, Bizikova P. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008–2011 update. Vet Dermatol. 2013;24:97-e26.
Olivry T, DeBoer D, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210.
Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol. 2011;11:420-427.
Rahman S, Collins M, Williams CMM, Ma HL. The pathology and immunology of atopic dermatitis. In amm Allergy Drug Targets. 2011;10:486-496.
400
42ND WORLD SMALL ANIMAL VETERINARY ASSOCIATION CONGRESS AND FECAVA 23RD EUROCONGRESS


































































































   398   399   400   401   402